The mission of the CARE Consortium is to encourage collaboration and innovation in research among a diverse network of nationally recognized cancer centers. The CARE Consortium connects investigators and their research activities primarily related to the development of progressive studies that include molecular diagnostics treatments. Patients may access pioneering, targeted therapies through the consortium, while doctors receive invaluable information to accelerate translational and advanced cancer research.
The CARE Consortium consists of experts in cancer stem cells, genomics, tumor models, circulating biomarkers, novel biopsy techniques and drug development. Studies include:
- Triple negative breast cancer
- Non-small cell lung cancer
- Melanoma
Consortium investigators have access to the pooled resources of the CARE tissue bank, and investigators can submit proposals to the CARE board for consideration of use for trial. Housed at the individual institutions of the consortium, the most compelling proposals receive access to appropriate tissues from the tissue bank.
Expediting Research
The CARE Consortium pools expertise and resources across some of the nation’s top research institutions to accelerate the translation of basic cancer research into clinical practice. Consortium member institutions are developing a new model to implement effective, personalized therapy by incorporating innovative molecular diagnostics, targeted therapeutic interventions and advanced statistical trial design.
The CARE Consortium helps to curtail the time-consuming steps that often slow multicenter trial development. By offering institutional review board reciprocity among consortium institutions and streamlined contracts with funding agencies, the consortium can bring trials to patients eight to 12 months faster.